246 related articles for article (PubMed ID: 25616318)
1. Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.
Hefti E; Blanco JG
Cardiovasc Toxicol; 2016 Jan; 16(1):5-13. PubMed ID: 25616318
[TBL] [Abstract][Full Text] [Related]
2. Analysis of mtDNA, miR-155 and BACH1 expression in hearts from donors with and without Down syndrome.
Hefti E; Quiñones-Lombraña A; Redzematovic A; Hui J; Blanco JG
Mitochondrial DNA A DNA Mapp Seq Anal; 2016; 27(2):896-903. PubMed ID: 24938108
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
4. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
5. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline-related acute cardiotoxicity in a very young Omani patient with acute myeloid leukaemia.
Tony S; Mevada R; Joshi N
Cardiol Young; 2021 Mar; 31(3):464-467. PubMed ID: 33228820
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline cardiotoxicity.
Jones RL; Swanton C; Ewer MS
Expert Opin Drug Saf; 2006 Nov; 5(6):791-809. PubMed ID: 17044806
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
[TBL] [Abstract][Full Text] [Related]
9. Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.
Vandecruys E; Mondelaers V; De Wolf D; Benoit Y; Suys B
J Cancer Surviv; 2012 Mar; 6(1):95-101. PubMed ID: 21630046
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
11. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
12. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
14. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
[TBL] [Abstract][Full Text] [Related]
15. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
17. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
Salvatorelli E; Menna P; Minotti G
Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550
[No Abstract] [Full Text] [Related]
18. HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.
Vaitiekus D; Muckiene G; Vaitiekiene A; Sereikaite L; Inciuraite R; Insodaite R; Cepuliene D; Kupcinskas J; Ugenskiene R; Jurkevicius R; Juozaityte E
Cardiovasc Toxicol; 2021 Jan; 21(1):59-66. PubMed ID: 32748118
[TBL] [Abstract][Full Text] [Related]
19. Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.
Zhou X; Weng Y; Jiang T; Ou W; Zhang N; Dong Q; Tang X
BMC Cancer; 2023 Oct; 23(1):976. PubMed ID: 37833648
[TBL] [Abstract][Full Text] [Related]
20. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
